ClinicalTrials.gg
RecruitingNCT07359105Updated Mar 10, 2026

Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)

An interventional study of Moderate-intensity statin monotherapy and Ezetimibe or ezetimibe-statin combination therapy in Dyslipidemia Associated With Type II Diabetes Mellitus, sponsored by Sin Gon Kim. Recruiting at 2 sites in South Korea. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Sin Gon Kim · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,186
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.

Planned enrollment
7th of 124
2,186 · median 80
Started
2026
with 7 others
No phase
13 of 155
6 open now
Primary completion
2029-12
later than 36 of 38 live
Registered
143rd of 155
by date

Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 7th largest by planned enrollment of the 124 interventional ones that give a count, is one of 8 that started in 2026, is one of 13 with no phase, reaches primary completion later than 36 of the 38 other live ones, and was the 143rd registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Dyslipidemias with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Statins are the cornerstone of cardiovascular disease (CVD) prevention through the lowering of low-density lipoprotein cholesterol (LDL-C). While the benefits of intensive LDL-C lowering are well-established for secondary prevention, evidence remains insufficient for primary prevention in the elderly-specifically for individuals aged 70 years or older with type 2 diabetes who have no prior history of atherosclerotic cardiovascular events.

Current guidelines generally recommend moderate-intensity statins for this population based on extrapolated data. However, there is a significant evidence gap regarding whether these older adults, who have not yet experienced a cardiovascular event, derive the same risk-benefit ratio from pharmacological intervention as younger or secondary prevention groups. Furthermore, while ezetimibe (alone or in combination) is an effective alternative for patients with established disease, its efficacy as a primary prevention strategy in older diabetic patients has not been rigorously confirmed through randomized controlled trials (RCTs).

Therefore, this study specifically focuses on the primary prevention setting, aiming to determine whether individualized LDL-C target-based therapy is non-inferior to standard moderate-intensity statin therapy in preventing first-time cardiovascular events among older patients with type 2 diabetes.

03

Conditions studied

  • Dyslipidemia Associated With Type II Diabetes Mellitus

Keywords

  • Dyslipidemia
  • T2D
  • Diabetes
  • Statins
  • iTARGET-Elderly
  • RRCT
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written to participate in the study by the patient or his/her legally authorized representative after receiving and understanding a detailed explanation of the study
  • Adults aged 70 years or older
  • Diagnosed with type 2 diabetes or currently receiving antidiabetic medication, without a history or presence of cardiovascular disease
  • Either: (1) LDL-C≥100 mg/dL if not receiving lipid-lowering therapy, or (2) currently receiving lipid-lowering therapy (in this case, LDL-C level not restricted)

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 1 diabetes
  • Documented history of atherosclerotic cardiovascular disease at screening, confirmed clinically or by imaging: (1) myocardial infarction; (2) coronary revascularization; (3) currently receiving treatment for acute coronary syndrome; (4) history of ischemic stroke; (5) aortic aneurysm; (6) peripheral arterial disease
  • Currently undergoing cancer treatment
  • Severe disease requiring recurrent hospitalization
  • Frailty (defined as a score ≥3 on the Korean FRAIL questionnaire), or any condition significantly limiting self-care
  • or ALT >3 × , at screening (however, patients will be eligible if repeat testing at the time of randomization shows levels \<3 × ULN), or liver cirrhosis
  • to study drugs
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,186 participants (estimated)

Study arms

  • Active comparator
    Moderate-intensity statin monotherapy arm

    Statin monotherapy with approved medications.

    Drug: Moderate-intensity statin monotherapy

  • Experimental
    Individualized LDL-C target-based therapy arm

    The investigator will establish individualized LDL-C targets (\<55 mg/dL or \<70 mg/dL or \<100 mg/dL) by considering each patient's cardiovascular risk, life expectancy, risk of adverse drug reactions, comorbidities, and personal preferences. The decision-making process will be shared with the patient to ensure that individual needs are addressed.

    Drug: Ezetimibe or ezetimibe-statin combination therapy

Interventions

  • DrugModerate-intensity statin monotherapy

    Atorvastatin 10 mg, 20 mg, or 40 mg, or rosuvastatin 5 mg, 10 mg, or 20 mg will be administered for up to 3 years. If the LDL-C is ≥100 mg/dL, the investigator may adjust the statin intensity based on the patient's health status.

  • DrugEzetimibe or ezetimibe-statin combination therapy

    Treatment will consist of non-pharmacological interventions or marketed medications, including low-dose statins (atorvastatin 5 mg or 10 mg, rosuvastatin 2.5 mg or 5 mg) in combination with ezetimibe 10 mg, or fixed-dose combinations (rosuvamibe 10/2.5 mg, atorvabmibe 10/5 mg, or Rosuzet 10/2.5 mg), for up to 3 years. If the pre-specified LDL-C target is not achieved or drug intolerance occurs, adjustments in dosage or medication will be made.

06

What researchers measure

Primary outcomes

  1. Time from the date of randomization to the first occurrence of a major adverse cardiovascular event (MACE)

    Major adverse cardiovascular event (MACE) includes death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, hospitalization due to heart failure, coronary revascularization, or all-cause death.

    Time frame: 0, 3, 12, 24, 36 months

Secondary outcomes

  1. Time from the date of randomization to the first hospitalization due to the following events or to the first occurrence of such events, whichever occurs earlier : (1) ischemic heart disease, (2) cerebrovascular disease, (3) heart failure, (4) peripheral

    Time frame: 0, 3, 12, 24, 36 months

  2. Time from the date of randomization to the first occurrence of all-cause hospitalization or all-cause death, whichever occurs first

    Time frame: 0, 3, 12, 24, 36 months

  3. Serum lipid levels from baseline at each assessment time point

    Time frame: 0, 3, 12, 24, 36 months

  4. Serum lipid changes from baseline at each assessment time point

    Time frame: 0, 3, 12, 24, 36 months

  5. Patterns of study drug use

    Time frame: From baseline up to 36 months

  6. Incidence rates and characteristics of adverse events, adverse drug reactions, and serious adverse events

    Time frame: From baseline up to 36 months

  7. Incidence rates and characteristics of adverse events of special interest (AESI)

    Adverse events of special interest (AESI): (1) Elevation of aminotransferase levels, (2) Rhabdomyolysis/myopathy, (3) Gastrointestinal problems

    Time frame: From baseline up to 36 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2029, 45 months after the start.

Of 194 non-industry interventional studies with no phase under Dyslipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 45 months is above that.

Counting every sponsor, half of 205 studies reached it within 16 months; a quarter within 8 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 22, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359105
Lead sponsor
Sin Gon Kim
Responsible party
Sin Gon Kim (Professior, Department of Endocrinology and metabolism, Korea University Anam Hospital, South Korea, Korea University Anam Hospital) — Sponsor-investigator
First posted
Jan 22, 2026
Start date
Mar 9, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 10, 2026

Study contacts

Kim
Contact
aakmcaaec002@kumc.or.kr
82-2-920-6791
Sin Gon Kim, MD
principal investigator · Korea University Anam Hospital
Bong-Soo Cha, MD
principal investigator · Severance Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion